School Committee learns more about GLP-1 insurance coverage decision
GLP-1, short for glucagon-like peptide-1, is a type of medication based on the hormone of the same name that helps regulate blood sugar and appetite by stimulating insulin release and slowing stomach emptying. Originally designed as weight loss drugs due to their ability to decrease appetite, the drugs have become effective tools for individuals battling diabetes as well.
During the
According to DeLacey, the cost of GLP-1 rose tenfold from Fiscal Year 2023 to 2025 and rose five times between Fiscal Year 2024 and 2025. DeLacey added that several health insurance carriers had lost hundreds of millions of dollars due in large part to the drug cost spike and that several nearby local government entities had stopped covering GLP-1 medications for cost reasons as well.
DeLacey went on to share a recent study showed that if these drugs were covered by Medicare, the annual national cost would be approximately
"It's just so cost prohibitive, for the return you get, it doesn't make a lot of sense," he said.
If the district were to offer these drugs, DeLacey estimated that it would cost the district an additional
DeLacey and Upton told the board that employees were not told that they couldn't obtain the drugs, only that they would no longer be covered under the district's health insurance. Employees could still obtain reimbursement for costs of the pills through health savings accounts, direct sales from manufacturers or other alternatives. It was noted there would be reviews of the drugs' costs in the future to see if they would become more affordable. Ward 2
Members of the board expressed frustration that they were unable to do more to help the staff members that came forward earlier in the month and appreciated that those staff members brought the issue to their attention.
Ward 4
Ward 5
"This was not a decision that was lightly made, it is incredibly difficult to make a cut like this," said O'Connell. "But when we're in a situation where the district does not necessarily have the budget that it needs and was requested, we have to make these kinds of decisions."



Gallego supports bill capping prices for medications
September 2025 Monthly
Advisor News
- SEC in ‘active and detailed’ settlement talks with accused scammer Tai Lopez
- Sketching out the golden years: new book tries to make retirement planning fun
- Most women say they are their household’s CFO, Allianz Life survey finds
- MassMutual reports strong 2025 results
- The silent retirement savings killer: Bridging the Medicare gap
More Advisor NewsAnnuity News
- Annexus and Americo Announce Strategic Partnership with Launch of Americo Benchmark Flex Fixed Indexed Annuity Suite
- Rethinking whether annuities are too late for older retirees
- Advising clients wanting to retire early: how annuities can bridge the gap
- F&G joins Voya’s annuity platform
- Regulators ponder how to tamp down annuity illustrations as high as 27%
More Annuity NewsHealth/Employee Benefits News
- Wellpoint taps Rachel Chinetti as president
- Proposed changes to MA and Part D would harm seniors’ coverage in 2027
- Pan-American Life Insurance Group Reports Record 2025 Results; Premiums Reached $1.86 Billion and Net Income Totaled $110 Million as Company Enters Its 115th Year
- LightSpun and Smile America Partners Announce Partnership to Accelerate Dental Provider Enrollment to Expand Treatment for 500K Underserved Kids
- Lawmakers try again to change ‘reflection in the mirror’ for cancer patients
More Health/Employee Benefits NewsLife Insurance News
- Annexus and Americo Announce Strategic Partnership with Launch of Americo Benchmark Flex Fixed Indexed Annuity Suite
- LIMRA: Individual life insurance new premium sets 2025 sales record
- How AI can drive and bridge the insurance skills gap
- Symetra Partners With Empathy to Offer Bereavement Support to Group Life Insurance Beneficiaries
- National Life Group Ranked Second by The Wall Street Journal in Best Whole Life Insurance Companies of 2026
More Life Insurance News